Research programme: liver disorder therapeutics - LISCure Biosciences/Mayo Clinic
Latest Information Update: 16 Jan 2022
At a glance
- Originator LISCure Biosciences; Mayo Clinic
- Class Anti-inflammatories; Hepatoprotectants
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Liver disorders; Primary sclerosing cholangitis
Most Recent Events
- 06 Jan 2022 LISCure Biosciences and Mayo Clinic agree to co-develop microbiome based therapeutics for Liver disorders
- 01 Jan 2022 Early research in Liver disorders in USA, South Korea (unspecified route)
- 01 Jan 2022 Early research in Primary sclerosing cholangitis in South Korea, USA (unspecified route)